LITT for Ultra-early GBM Recurrence

Recruiting now · Not applicable

Conditions studied: Glioblastoma (GBM), Glioblastoma - Category

In brief

Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.

Key facts

Study ID

NCT07616986

Run by

Insel Gruppe AG, University Hospital Bern

People needed

12

Starts

2026-02-06

Expected to finish

2028-01-31

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
• ≥18 years of age
• CRET
• Karnofsky Performance Status (KPS) ≥70
• No contra-indication for radio-chemotherapy
• Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
• Able to provide informed consent
• No contra-indication for LITT
• No pregnancy or active breast-feeding
• No known coagulopathy independent of medication
• No dissemination or multifocal disease
• Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.

Where it is running

• Dep. of Neurosurgery, Bern University Hospital — Bern, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.